BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Eisai Inc. 

100 Tice Boulevard

Woodcliff Lake  New Jersey  07677  U.S.A.
Phone: 201-692-1100 Fax: 201-692-1804


View Clinical Trials from BioPharm Insight

Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit

For more information about Eisai, please visit

 Key Statistics

Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: Approximately 2,600
Symbol: ESALF.PK


 Company News
Eisai Inc. (ESALF.PK) Launches National Television Advertising Campaign For BELVIQ® (lorcaserin HCl) CIV 4/14/2014 8:05:37 AM    More...
Eisai Inc. (ESALF.PK) Reports Improved Patient Access For BELVIQ® (lorcaserin HCI) CIV 2/10/2014 10:19:28 AM    More...
Eisai Inc. (ESALF.PK) Announces U.S. Availability Of FYCOMPA™ (Perampanel) CIII An Adjunctive Treatment For Partial-Onset Seizures In Patients With Epilepsy Age 12 And Older 1/2/2014 8:49:13 AM    More...
Eisai Company, Ltd. (ESALY.PK) Joins Groundbreaking Tuberculosis Drug Accelerator Partnership To Discover New Tuberculosis Drugs 11/26/2013 9:05:27 AM    More...
Eisai Inc. (ESALF.PK) Release: BELVIQ® (lorcaserin HCl) CIV Data Featured In Five Abstracts To Be Presented At Obesityweek(SM) 2013 11/14/2013 10:56:22 AM    More...
Eisai Inc. (ESALF.PK) Announces Availability of ACIPHEX® Sprinkle™ (Rabeprazole Sodium) for Treatment of GERD in Children Ages 1 to 11 11/8/2013 10:08:01 AM    More...
Arena Pharmaceuticals, Inc. (ARNA) Expands Deal With Eisai Inc. (ESALF.PK) on Sales of Obesity Drug 11/8/2013 7:05:53 AM    More...
Arena Pharmaceuticals, Inc. (ARNA) Provides Update as Eisai Inc. (ESALF.PK)'s Launch of BELVIQ® (lorcaserin HCl) CIV Enters Consumer Phase 9/16/2013 10:08:33 AM    More...
Eisai Inc. (ESALF.PK) Takes Legal Action in Federal Court Alleging Unreasonable Delay in DEA Scheduling of FYCOMPA™ (perampanel) 8/20/2013 7:22:17 AM    More...
Eisai Inc. (ESALF.PK) Launches New Website Providing Employers With Educational Resource for Obesity Management 8/16/2013 9:02:30 AM    More...